MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPEJune 26, 2024
Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”AL amyloidosis, MPEMarch 27, 2024
EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisationAccess, MPEDecember 15, 2023
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, MyelomaDecember 8, 2023
MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPENovember 21, 2023
MPE to present at European Society for Medical Oncology (ESMO) Annual Congress 2023Conferences, MPEOctober 17, 2023
